Current Issue

Volume 2, Issue 1 - 2017

Research Article

Using Immune Cells for Transport of Therapeutics to Brain Tumors

Corresponding Author: Elena V. Batrakova, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill
Citation: Batrakova EV. (2017). Using Immune Cells for Transport of Therapeutics to Brain Tumors. M J Canc. 2(1): 008.

PDF    Full Text

Research Article

Anticancer Potential of EDTA: A Preliminary in Vitro Study

Corresponding Author: Loreto B. Feril Jr, Department of Anatomy, Fukuoka University School of Medicine, Fukuoka, Japan
Citation: Feril LB Jr, Ogawa K, Watanabe A, Ogawa R, et al. (2017). Anticancer Potential of EDTA: A Preliminary in Vitro Study. M J Canc. 2(1): 009.

PDF    Full Text

Research Article

Flow Cytometric Analysis of Hyperfractionated and Hypofractionated Radiotherapy for Breast Cancer Patients

Corresponding Author: Hossam Donya, Medical Physics Division, Physics Department, King Abdulaziz University, Jeddah 21589, Saudi Arabia and Physics Department, Faculty of Science, Menoufia University, Shebin El-Koom 32512, Egypt
Citation: Donya H and Moawad M. (2017). Flow Cytometric Analysis of Hyperfractionated and Hypofractionated Radiotherapy for Breast Cancer Patients. M J Canc. 2(1): 010.

PDF    Full Text

Research Article

Burden of Merkel Cell Carcinoma: A Targeted Literature Review

Corresponding Author: Siva Narayanan, Executive Vice President, MKTXS Market Access Solutions, LLC, 575 West Rt. 28, Suite 207, Raritan, NJ 08807, USA
Citation: Narayanan S and Gala S. (2017). Burden of Merkel Cell Carcinoma: A Targeted Literature Review. M J Canc. 2(1): 011.

PDF    Full Text

Research Article

Initial Response to Therapy with Fulvestrant and Cyclin-Dependent Kinase 4/6 Inhibitor in a Male with Stage IV Breast Cancer

Corresponding Author: Aurelio B. Castrellon, Memorial Healthcare System, Memorial Cancer Institute, Breast Center, Director of Breast Cancer Research, Florida USA
Citation: Castrellon AB, Nguyen SM, Milillo Naraine AM, Velez M, et al. (2017). Initial Response to Therapy with Fulvestrant and Cyclin-Dependent Kinase 4/6 Inhibitor in a Male with Stage IV Breast Cancer. M J Canc. 2(1): 012.

PDF    Full Text

Give us some quick information and we'll point you in the right direction.